PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
16.30%
Revenue growth above 1.5x AVGO's 6.32%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
16.08%
Gross profit growth above 1.5x AVGO's 4.96%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
26.27%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
26.27%
Operating income growth above 1.5x AVGO's 1.00%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
24.62%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
157.14%
Positive EPS growth while AVGO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
150.00%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-48.95%
Share reduction while AVGO is at 0.15%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-49.43%
Reduced diluted shares while AVGO is at 0.70%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-26.53%
Negative OCF growth while AVGO is at 9.32%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-32.27%
Negative FCF growth while AVGO is at 9.56%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
82.27%
10Y revenue/share CAGR under 50% of AVGO's 416.86%. Michael Burry would suspect a lasting competitive disadvantage.
82.27%
5Y revenue/share CAGR at 50-75% of AVGO's 134.28%. Martin Whitman would worry about a lagging mid-term growth trajectory.
82.27%
3Y revenue/share CAGR 1.25-1.5x AVGO's 62.33%. Bruce Berkowitz might see better product or regional expansions than the competitor.
50.24%
10Y OCF/share CAGR under 50% of AVGO's 580.47%. Michael Burry would worry about a persistent underperformance in cash creation.
50.24%
5Y OCF/share CAGR at 50-75% of AVGO's 92.77%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
50.24%
3Y OCF/share CAGR 1.25-1.5x AVGO's 39.51%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
136.25%
Below 50% of AVGO's 869.72%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
136.25%
Below 50% of AVGO's 414.43%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
136.25%
3Y net income/share CAGR above 1.5x AVGO's 16.00%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
227.76%
Below 50% of AVGO's 862.23%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
227.76%
5Y equity/share CAGR 1.25-1.5x AVGO's 165.61%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
227.76%
3Y equity/share CAGR 1.25-1.5x AVGO's 201.93%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.63%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
36.78%
Inventory growth well above AVGO's 8.08%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
93.88%
Asset growth above 1.5x AVGO's 0.60%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
243.60%
BV/share growth above 1.5x AVGO's 5.15%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
16866.72%
We have some new debt while AVGO reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
9.34%
R&D growth drastically higher vs. AVGO's 13.26%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
1.71%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.